{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:40:14Z","timestamp":1778121614971,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008630.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000}}],"reference-count":111,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008630.pub5","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:10:37Z","timestamp":1579950637000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome"],"prefix":"10.1002","volume":"2020","author":[{"given":"Alex Y","family":"Doets","sequence":"first","affiliation":[{"name":"Erasmus University Medical Centre; P.O. Box 2040 University Medical Centre Rotterdam Rotterdam Netherlands 3000 CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard AC","family":"Hughes","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; PO Box 114 Queen Square London UK WC1N 3BG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; Queen Square Centre for Neuromuscular Diseases; PO Box 114 London UK WC1N 3BG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert DM","family":"Hadden","sequence":"additional","affiliation":[{"name":"King's College Hospital; Department of Neurology; Denmark Hill London UK SE5 9RS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Charing Cross Hospital; Neuromuscular Unit 3 North; Fulham Palace Road London UK W6 8RF"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-1331.2000.00096.x","article-title":"Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barr\u00e9 syndrome: a pilot study","volume":"7","author":"Bensa","year":"2000","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0003|cit2","first-page":"267","article-title":"Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0002|cit3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jns.12083","article-title":"A double blind, randomised controlled phase II trial of complement inhibition in Guillain-Barr\u00e9 syndrome","volume":"19","author":"Davidson","year":"2014","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0005|cit5","unstructured":"NCT02029378 Inhibition of complement activation (eculizumab) in Guillain-Barr\u00e9 syndrome study (ICA-GBS) clinicaltrials.gov\/ct2\/show\/NCT02029378"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0006|cit6","unstructured":"eudract_number:2013-000228-33 Inhibition of complement activation (eculizumab) in Guillain-Barr\u00e9 syndrome study (ICA-GBS) www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-000228-33 2013"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0007|cit7","first-page":"187","article-title":"Japanese eculizumab trial for Guillain-Barr\u00e9 syndrome (JET-GBS)","volume":"21","author":"Kuwabara","year":"2016","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0008|cit8","first-page":"323","article-title":"Japanese eculizumab trial for Guillain-Barr\u00e9 syndrome (JET-GBS)","volume":"22","author":"Kuwabara","year":"2017","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"12","key":"10.1002\/14651858.CD008630.pub5-BIB0009|cit9","first-page":"1423","article-title":"Novel therapy in Guillain-Barr\u00e9 syndrome","volume":"68","author":"Kuwahara","year":"2016","journal-title":"Brain and Nerve"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008630.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2017.08.527","article-title":"Eculizumab for Guillain-Barr\u00e9 syndrome: randomized clinical trial (JET-GBS study)","volume":"381","author":"Misawa","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0012|cit12","unstructured":"NCT02493725 JET-GBS - Japanese eculizumab trial for GBS clinicaltrials.gov\/ct2\/show\/NCT02493725"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.2196\/resprot.6610","article-title":"A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barr\u00e9 syndrome (GBS): protocol of Japanese eculizumab trial for GBS (JET-GBS)","volume":"5","author":"Yamaguchi","year":"2016","journal-title":"JMIR Research Protocols"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008630.pub5-BIB0014|cit14","first-page":"52","article-title":"A pilot randomised, double-blind, placebo-controlled exploratory safety study of the use of interferon-beta 1a in the treatment of Guillain-Barr\u00e9 syndrome","volume":"8","author":"Pritchard","year":"2003","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"9","key":"10.1002\/14651858.CD008630.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1212\/WNL.57.5.774","article-title":"CSF filtration is an effective treatment of Guillain-Barr\u00e9 syndrome: a randomized clinical trial","volume":"57","author":"Wollinsky","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0017|cit17","first-page":"332","article-title":"Effect of tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome","volume":"20","author":"Zhang","year":"2000","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0018|cit18","first-page":"186","article-title":"Cyclophosphamide in Landry-Guillain-Barr\u00e9 syndrome","volume":"2","author":"Ahuja","year":"1980","journal-title":"Acta Neurologica"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12028-011-9536-5","article-title":"Selective digestive tract decontamination decreases time on ventilator in Guillain-Barre syndrome","volume":"15","author":"Bos Eyssen","year":"2011","journal-title":"Neurocritical Care"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(65)90479-4","article-title":"6-mercaptopurine in polyradiculoneuropathy","volume":"2","author":"Colin-Jones","year":"1965","journal-title":"Lancet"},{"issue":"9125","key":"10.1002\/14651858.CD008630.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(05)60466-7","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with interferon-beta","volume":"352","author":"Cr\u00e9ange","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00044011-199510060-00001","article-title":"L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients","volume":"10","author":"Grandis","year":"1995","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0023|cit23","unstructured":"Ding F 27 cases with infantile Guillain-Barre syndrome treated with acupuncture combined with hyperbaric oxygen therapy Henan Traditional Chinese Medicine [He Nan Zhong Yi] 2015 155 7"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/jnnp.54.1.51","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with anti-T cell monoclonal antibodies","volume":"54","author":"Feasby","year":"1991","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0025|cit25","first-page":"253","article-title":"Clinical trial of a new coenzymatic complex (Ro 8-0743-4)","volume":"62","author":"Francesconi","year":"1972","journal-title":"Clinica Terapeutica"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(66)92410-X","article-title":"Mercaptopurine in polyradiculoneuropathy","volume":"i","author":"Gamstorp","year":"1966","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0028|cit27","first-page":"S24","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with intravenous immunoglobulins and methylprednisolone combined with mycophenolate (CELLCEPT) - a pilot study","volume":"10","author":"Garssen","year":"2005","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"9","key":"10.1002\/14651858.CD008630.pub5-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"2007","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0029|cit29","first-page":"22","article-title":"The use of pulsed and continuous UHF electrical fields in the rehabilitation of patients with the Guillain-Barre syndrome and other peripheral myelinopathies","volume":"95","author":"Gorbunov","year":"1995","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1378\/chest.104.2.547","article-title":"Neurologic disease requiring long-term ventilation. The role of selective decontamination of the digestive tract in preventing nosocomial infection","volume":"104","author":"Hammond","year":"1993","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01706436","article-title":"Air fluidization therapy of pressure sores due to Guillain-Barre and Cushing syndrome","volume":"18","author":"Hilz","year":"1992","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0032|cit32","first-page":"119","article-title":"Ultraviolet rays for Guillain-Barre syndrome","volume":"21","author":"Huang","year":"1998","journal-title":"Chinese Journal of Physical Therapy"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0033|cit33","first-page":"123","article-title":"Ultraviolet radiation and oxygen enrichment self-blood transfusion therapy for Guillain-Barre syndrome","volume":"31","author":"Huang","year":"1998","journal-title":"Chinese Journal of Neurology"},{"issue":"26","key":"10.1002\/14651858.CD008630.pub5-BIB0034|cit34","first-page":"714","article-title":"Treatment of polyneuropathies. Investigations on efficacy of Ginkgo biloba extract EGb 761 in patients with polyneuropathy","volume":"69","author":"Husstedt","year":"1993","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0035|cit35","first-page":"178","article-title":"Ultraviolet rays for Guillain-Barr\u00e9 syndrome","volume":"21","author":"Li","year":"1998","journal-title":"Chinese Journal of Physical Therapy"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0036|cit36","first-page":"604","article-title":"Lymphoplasmapheresis for Guillain-Barre syndrome","volume":"32","author":"Li","year":"2007","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban. Yi Xue Ban = Journal of Central South University. Medical Sciences"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0037|cit37","first-page":"1293","article-title":"The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain-Barr\u00e9 syndrome: a double-blind cross-over phase I drug trial","volume":"81","author":"Meythaler","year":"2000","journal-title":"Archives of Physical Medicine & Rehabilitation"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0038|cit38","unstructured":"NCT03773328 Phase 1 trial to evaluate the safety of CK0801 in treatment-resistant Guillain-Barr\u00e9 syndrome (GBS) clinicaltrials.gov\/ct2\/show\/NCT03773328"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/bmt.2008.81","article-title":"Rituximab-responsive Guillain-Barre syndrome following allogeneic hematopoietic SCT","volume":"42","author":"Ostronoff","year":"2008","journal-title":"Bone Marrow Transplantation"},{"issue":"7388","key":"10.1002\/14651858.CD008630.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(65)92091-X","article-title":"Polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome) treated with 6-mercaptopurine","volume":"1","author":"Palmer","year":"1965","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(66)90085-7","article-title":"Polyneuropathy treated with cytotoxic drugs","volume":"1","author":"Palmer","year":"1966","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0022-510X(76)90265-3","article-title":"Clinical effects of cyclophosphamide in Guillain-Barre polyneuritis","volume":"30","author":"Rosen","year":"1976","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000050798","article-title":"Successful treatment of Guillain-Barr\u00e9 syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin","volume":"46","author":"Schaller","year":"2001","journal-title":"European Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/09638288.2012.687031","article-title":"Effect of pranayama and meditation as an add-on therapy in rehabilitation of patients with Guillain-Barre syndrome--a randomized control pilot study","volume":"35","author":"Sendhilkumar","year":"2013","journal-title":"Disability and Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000358292","article-title":"Successful treatment of refractory Guillain-Barr\u00e9 syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia","volume":"132","author":"Tzachanis","year":"2014","journal-title":"Acta Haematology"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"250\u201389","DOI":"10.1111\/jns.12083","article-title":"Can antibiotics improve outcome in diarrhea-associated Guillain-Barr\u00e9 syndrome?: a double-blind, placebo controlled randomised study","volume":"19","author":"Umapathi","year":"2014","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0047|cit47","first-page":"124","article-title":"Electroacupuncture at shu-points of the five zang-organs for treatment of the flaccidity syndrome","volume":"10","author":"Wang","year":"2006","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"7 (Suppl)","key":"10.1002\/14651858.CD008630.pub5-BIB0048|cit48","first-page":"746","article-title":"Clinical trial of \"F.E.V. 300\". Apropos of 300 cases","volume":"12","author":"Warembourg","year":"1967","journal-title":"Lille Medical"},{"issue":"7678","key":"10.1002\/14651858.CD008630.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(70)92019-2","article-title":"Treatment of polyneuropathy with azathioprine","volume":"2","author":"Yuill","year":"1970","journal-title":"Lancet"},{"issue":"9-10","key":"10.1002\/14651858.CD008630.pub5-BIB0050|cit50","first-page":"246","article-title":"Treatment of Guillain-Barr\u00e9 syndrome","volume":"117","author":"Zagar","year":"1995","journal-title":"Lijecnicki Vjesnik"},{"issue":"Suppl","key":"10.1002\/14651858.CD008630.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.53.2.409","article-title":"Residual physical outcome and daily living 3 to 6 years after Guillain-Barr\u00e9 syndrome","volume":"53","author":"Bernsen","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF00375050","article-title":"The acute paralysis in Guillain-Barr\u00e9 syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid","volume":"421","author":"Brinkmeier","year":"1992","journal-title":"Pflugers Archiv: European Journal of Physiology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/mus.24608","article-title":"Two steps forward one step back: mycophenolate mofetil use for myasthenia gravis in the United States","volume":"51","author":"Burns","year":"2015","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001798.pub3","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Chevret","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1212\/01.WNL.0000042423.36650.BD","article-title":"The pentapeptide QYNAD does not block voltage-gated sodium channels","volume":"60","author":"Cummins","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000022.pub3","article-title":"Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care","author":"D'Amico","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0058|cit58","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) Available from handbook-5-1.cochrane.org\/"},{"issue":"10","key":"10.1002\/14651858.CD008630.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/09546634.2014.880395","article-title":"Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus","volume":"26","author":"Doukaki","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"23","key":"10.1002\/14651858.CD008630.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1212\/WNL.57.5.753","article-title":"Drain the roots: a new treatment for Guillain-Barr\u00e9 syndrome?","volume":"57","author":"Feasby","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"Journal of the Peripheral Nervous Systystem"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-151-4-200908180-00005","article-title":"Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial","volume":"151","author":"Goldbach-Mansky","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008630.pub5-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","article-title":"Guillain-Barr\u00e9 syndrome: a century of progress","volume":"12","author":"Goodfellow","year":"2016","journal-title":"Nature Reviews Neurology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0066|cit66","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT accessed March 2019"},{"issue":"5","key":"10.1002\/14651858.CD008630.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ana.20546","article-title":"Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome","volume":"58","author":"Halstead","year":"2005","journal-title":"Annual Neurology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Halstead SK Zitman FM Humphreys PD Greenshields K Verschuuren JJ Jacobs BC Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model Brain 2008 1197 208","DOI":"10.1093\/brain\/awm316"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0071|cit71","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook-5-1.cochrane.org\/"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0072|cit72","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook-5-1.cochrane.org\/"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0073|cit73","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Churchill R Methodological expectations of Cochrane intervention reviews Cochrane: London, Version 1.06. 2018"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub5-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"8093","key":"10.1002\/14651858.CD008630.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"issue":"Pt 9","key":"10.1002\/14651858.CD008630.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"issue":"9","key":"10.1002\/14651858.CD008630.pub5-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008630.pub5-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub5","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jns.12209","article-title":"International Guillain-Barr\u00e9 Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr\u00e9 syndrome","volume":"22","author":"Jacobs","year":"2017","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"23","key":"10.1002\/14651858.CD008630.pub5-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/brain\/awq179","article-title":"Functional role of brain derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis","volume":"133","author":"Linker","year":"2010","journal-title":"Brain"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0082|cit82","unstructured":"Ludolph A Information Email to: RAC Hughes"},{"issue":"11","key":"10.1002\/14651858.CD008630.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/jnnp.2009.194324","article-title":"Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance","volume":"81","author":"Merkies","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3-4","key":"10.1002\/14651858.CD008630.pub5-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000445347","article-title":"Fatigue, pain, anxiety and depression in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"75","author":"Merkies","year":"2016","journal-title":"European Neurology"},{"issue":"7","key":"10.1002\/14651858.CD008630.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/1570159X14666161213114904","article-title":"Biological drugs in Guillain-Barr\u00e9 syndrome: an update","volume":"15","author":"Motamed-Gorji","year":"2017","journal-title":"Current Neuropharmacology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0086|cit86","unstructured":"NCT03943589 A study of imlifidase in patients with Guillain-Barr\u00e9 syndrome clinicaltrials.gov\/ct2\/show\/NCT03943589"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0087|cit87","unstructured":"NCT04035135 A clinical study of ANX005 and IVIg in subjects with Guillain-Barr\u00e9 syndrome (GBS) clinicaltrials.gov\/ct2\/show\/NCT04035135"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1017\/S0317167100004248","article-title":"The pentapeptide QYNAD does not inhibit neuronal network activity","volume":"32","author":"Otto","year":"2005","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"9047","key":"10.1002\/14651858.CD008630.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"issue":"9-10","key":"10.1002\/14651858.CD008630.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.nmd.2014.06.389","article-title":"Novel use of eculizumab in a patient with Guillain\u2013Barr\u00e9 syndrome","volume":"24","author":"Ram","year":"2014","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD008630.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jnnp.64.1.74","article-title":"Epidemiological study of Guillain-Barr\u00e9 syndrome in south east England","volume":"64","author":"Rees","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0092|cit92","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0094|cit94","unstructured":"Roche Products Limited Cellcept 500mg Film-Coated Tablets www.medicines.org.uk\/emc\/medicine\/1680 Accessed 2 November 2016 2015"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0096|cit96","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook-5-1.cochrane.org\/"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0097|cit97","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook-5-1.cochrane.org\/"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3138\/ptc.2015-58","article-title":"Influence of exercise on patients with Guillain-Barre syndrome: a systematic review","volume":"68","author":"Simatos Arsenault","year":"2016","journal-title":"Physiotherapy Canada"},{"issue":"6","key":"10.1002\/14651858.CD008630.pub5-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922.pub4","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"18","key":"10.1002\/14651858.CD008630.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barr\u00e9 syndrome","volume":"80","author":"Berg","year":"2013","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Berg","year":"2014","journal-title":"Nature Reviews Neurology"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial","volume":"363","author":"Koningsveld","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008630.pub5-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"Nes","year":"2011","journal-title":"Neurology"},{"issue":"10045","key":"10.1002\/14651858.CD008630.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008630.pub5-BIB0105|cit105","first-page":"95","article-title":"Clinical experiences with CSF filtration in Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy and multiple sclerosis","volume":"9","author":"Wollinsky","year":"1995","journal-title":"Neuropsychiatrie"},{"issue":"24","key":"10.1002\/14651858.CD008630.pub5-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1097-4547(19990415)56:2<123::AID-JNR2>3.0.CO;2-G","article-title":"IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue","volume":"56","author":"Zou","year":"1999","journal-title":"Journal of Neuroscience Research"},{"issue":"8","key":"10.1002\/14651858.CD008630.pub5-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008630","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barr\u00e9 syndrome","author":"Hughes","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008630.pub5-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008630.pub2","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barr\u00e9 syndrome","author":"Hughes","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008630.pub5-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008630.pub3","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008630.pub5-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008630.pub4","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Pritchard","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008630.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:16:30Z","timestamp":1749813390000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008630.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008630.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]}}}